Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features.
ELISA
SARS‐CoV‐2 antibodies
T follicular helper cells
antibody‐secreting cells
neutralisation assay
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
01
2021
revised:
01
02
2021
accepted:
03
02
2021
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
As the world transitions into a new era of the COVID-19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. We used 34 SARS-CoV-2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level-3 containment. We correlated results from the sVNT with five additional commonly used SARS-CoV-2 serology techniques: the microneutralisation test (MNT), in-house ELISAs, commercial Euroimmun- and Wantai-based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen-binding avidity, and high-throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody-secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers. Antibody data obtained with commercial ELISAs closely reflected results using in-house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike-specific IgG and IgA titres detected by both commercial and in-house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh-type 1 cell numbers correlated with spike and RBD-specific IgG antibodies measured by ELISAs and sVNT. Our comprehensive analyses provide important insights into SARS-CoV-2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS-CoV-2-specific humoral responses.
Identifiants
pubmed: 33680466
doi: 10.1002/cti2.1258
pii: CTI21258
pmc: PMC7916820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1258Informations de copyright
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
MAbs. 2010 Jan-Feb;2(1):53-66
pubmed: 20168090
J Clin Virol. 2021 Jan;134:104690
pubmed: 33253926
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Front Microbiol. 2014 Jun 12;5:285
pubmed: 24971078
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Cell Host Microbe. 2020 Jun 10;27(6):976-991.e11
pubmed: 32320678
Lancet Public Health. 2020 May;5(5):e261-e270
pubmed: 32220655
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
PLoS One. 2020 Oct 27;15(10):e0237548
pubmed: 33108380
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
Viruses. 2012 Sep;4(9):1438-76
pubmed: 23170167
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Curr HIV Res. 2017;15(3):202-215
pubmed: 28322167
Cell Host Microbe. 2016 Jun 8;19(6):800-13
pubmed: 27281570
Clin Chim Acta. 2020 Nov;510:687-690
pubmed: 32910980
J Infect Dis. 2020 Sep 14;222(8):1280-1288
pubmed: 32761124
Nat Commun. 2020 Nov 11;11(1):5703
pubmed: 33177504
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
J Clin Virol. 2020 Aug;129:104539
pubmed: 32679298
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Cell Rep Med. 2021 Mar 16;2(3):100208
pubmed: 33564749
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Cell Rep. 2021 Mar 2;34(9):108790
pubmed: 33596407
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Front Cell Infect Microbiol. 2018 Oct 08;8:343
pubmed: 30349811
J Clin Invest. 2020 Dec 1;130(12):6588-6599
pubmed: 32841212
Lancet Infect Dis. 2020 Oct;20(10):1151-1160
pubmed: 32559451
Int J Infect Dis. 2021 Feb;103:381-388
pubmed: 33310021